Annals of Oncology
Papers 10,000
1 page of 1,000 pages (10k results)
#1Jiaxin Niu (The University of Texas MD Anderson Cancer Center)H-Index: 7
#2Corinne Maurice-Dror (Rambam Health Care Campus)H-Index: 5
Last. Myung-Ju Ahn (SMC: Samsung Medical Center)H-Index: 86
view all 19 authors...
Abstract null null Background null In this first-in-human phase 1 study, we investigated the safety and efficacy of the anti–TIGIT antibody vibostolimab as monotherapy or in combination with pembrolizumab. null null null Methods null Part A enrolled patients with advanced solid tumors and part B enrolled patients with non–small cell lung cancer (NSCLC). Patients received vibostolimab 2.1-700 mg alone or with pembrolizumab 200 mg in part A and vibostolimab 200 mg alone or with pembrolizumab 200 m...
#1D.M. Alexandru (UAF: University of Agriculture Faisalabad)
Last. F. Iordache (UAF: University of Agriculture Faisalabad)
view all 6 authors...
#1Iris C. Kok (UMCG: University Medical Center Groningen)H-Index: 6
#2J.A. Hooiveld (UMCG: University Medical Center Groningen)H-Index: 1
Last. E.G.E. de Vries (UMCG: University Medical Center Groningen)H-Index: 22
view all 20 authors...
Background null Programmed cell death protein-1 (PD-1) antibody treatment is standard of care for melanoma and non-small cell lung cancer (NSCLC). Accurately predicting which patients will benefit is currently not possible. Tumor uptake and biodistribution of the PD-1 antibody might play a role. Therefore, we performed a positron emission tomography (PET) imaging study with zirconium-89 (89Zr) labeled pembrolizumab before PD-1 antibody treatment. null Patients and methods null Patients with adva...
#1Yohann Loriot (University of Paris-Saclay)H-Index: 58
#2Aurélien Marabelle (University of Paris-Saclay)H-Index: 66
Last. Caroline Even (University of Paris-Saclay)H-Index: 21
view all 19 authors...
ABSTRACT null null Background null Immune checkpoint blockers (ICBs) are now widely used in oncology. However, most patients do not derive benefit from these agents. Therefore, there is a crucial need to identify novel and reliable biomarkers of resistance to such treatments in order to prescribe potentially toxic and costly treatments only to patients with expected therapeutic benefits. In the wake of genomics, the study of proteins is now emerging as the new frontier for understanding real-tim...
#1I.M. Modlin (Yale University)H-Index: 17
Last. Lisa Bodei (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 25
view all 11 authors...
Background null Biomarkers are key tools in cancer management. In neuroendocrine tumors (NETs), Chromogranin A (CgA) was considered acceptable as a biomarker. We compared the clinical efficacy of a multigenomic blood biomarker (NETest) to CgA over a 5-year period. null null null Patients and methods null An observational, prospective, cross-sectional, multicenter, multinational, comparative cohort assessment. Cohort 1: NETest evaluation in NETs (n = 1684) and cancers, benign diseases, controls (...
#1Nadia HarbeckH-Index: 88
#2Priya Rastogi (University of Pittsburgh)H-Index: 37
Last. Joyce O'Shaughnessy (BUMC: Baylor University Medical Center)H-Index: 67
view all 5 authors...
#1Chiara Corti (IEO: European Institute of Oncology)H-Index: 8
#2G. Antonarelli (IEO: European Institute of Oncology)H-Index: 2
Last. Giuseppe Curigliano (IEO: European Institute of Oncology)H-Index: 80
view all 8 authors...
ABSTRACT null null Background null Coronavirus disease 2019 (COVID-19) has affected more than 210 million people worldwide. An optimal therapeutic approach for COVID-19 remains uncertain, to date. Since the history of cancer was linked to higher mortality rates due to COVID-19, the establishment of a safe and effective vaccine coverage is crucial in these patients. However, patients with cancer were mostly excluded from vaccine candidates’ clinical trials. This systematic review aims to investig...
#1Enrique Grande (The University of Texas MD Anderson Cancer Center)H-Index: 29
#2Bernard Escudier (Institut Gustave Roussy)H-Index: 109
#1Andrew Chow (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 23
#2Matthew D. Hellmann (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 81
#1Georgina V. Long (RNSH: Royal North Shore Hospital)H-Index: 110
#2A. Arance (UB: University of Barcelona)H-Index: 6
Last. C. Robert (Institut Gustave Roussy)H-Index: 21
view all 21 authors...
Abstract null null Background null Antitumor activity of ipilimumab or BRAF ± MEK inhibition (BRAFi ± MEKi) following pembrolizumab in melanoma is poorly characterized. null null null Patients and methods null In the phase 3 KEYNOTE-006 study, patients with unresectable stage III/IV melanoma received pembrolizumab 10 mg/kg once every 2 or 3 weeks (Q3W) or ipilimumab 3 mg/kg Q3W. The current post hoc analysis evaluates outcomes with ipilimumab or BRAFi ± MEKi as first subsequent systemic therapy ...
Top fields of study
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.